Cargando…
Acid-Base Homeostasis During Vasopressin V2 Receptor Antagonist Treatment in Autosomal Dominant Polycystic Kidney Disease Patients
Autores principales: | Heida, Judith E., Gansevoort, Ron T., Meijer, Esther |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938056/ https://www.ncbi.nlm.nih.gov/pubmed/33732999 http://dx.doi.org/10.1016/j.ekir.2020.12.021 |
Ejemplares similares
-
Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease
por: Bais, Thomas, et al.
Publicado: (2022) -
Somatostatin in renal physiology and autosomal dominant polycystic kidney disease
por: Messchendorp, A Lianne, et al.
Publicado: (2019) -
Author’s Reply to Correspondence: “Effect of Tolvaptan Treatment on Acid−Base Homeostasis in ADPKD Patients”
por: Heida, Judith E., et al.
Publicado: (2021) -
Raynaud's phenomenon triggered by the vasopressin V(2) receptor antagonist tolvaptan in a patient with autosomal dominant polycystic kidney disease and Sjögren's syndrome
por: Roca Oporto, F J, et al.
Publicado: (2021) -
Thiazide diuretics and the rate of disease progression in autosomal dominant polycystic kidney disease: an observational study
por: Kramers, Bart J, et al.
Publicado: (2020)